Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
In the past few decades, the incidence of endocervical adenocarcinomas (ECAs) has been on the
rise both in absolute numbers and overall proportion in cervical cancers. ECAs remain a
significant public health problem despite advances in treatment options. Patients with ECA
have a poorer survival rate than patients with squamous cell carcinoma (SCC), especially in
patients with metastatic tumors. In the newly published 2020 World Health Organization (WHO)
Classification of Female Genital Tumors, ECAs are subclassified into human
papillomavirus-associated (HPVA) and human papillomavirus-independent (HPVI) groups.
Meanwhile, PD-1/PD-L1 immunotherapy has been approved for the treatment of advanced cervical
cancer, but there are still many deficiencies. Therefore, we plan to use the new
classification of female genital tumors and conduct a clinical trial to explore the safety
and effectiveness of compound kushen injection combined with pabolizumab in the treatment of
metastatic, recurrent, persistent cervical adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University